90 related articles for article (PubMed ID: 17517901)
1. A selective cellular screening assay for B-Raf and c-Raf kinases.
Ish T; Sootome H; Yagi Y; Yamashita K; Noumi T; Noro N; Ishii T
J Biomol Screen; 2007 Sep; 12(6):818-27. PubMed ID: 17517901
[TBL] [Abstract][Full Text] [Related]
2. Identification of inhibitors of the kinase activity of oncogenic V600E BRAF in an enzyme cascade high-throughput screen.
Newbatt Y; Burns S; Hayward R; Whittaker S; Kirk R; Marshall C; Springer C; McDonald E; ; Marais R; Workman P; Aherne W
J Biomol Screen; 2006 Mar; 11(2):145-54. PubMed ID: 16361694
[TBL] [Abstract][Full Text] [Related]
3. Allosteric Kinase Inhibitors Reshape MEK1 Kinase Activity Conformations in Cells and In Silico.
Fleischmann J; Feichtner A; DeFalco L; Kugler V; Schwaighofer S; Huber RG; Stefan E
Biomolecules; 2021 Mar; 11(4):. PubMed ID: 33808483
[TBL] [Abstract][Full Text] [Related]
4. Dimerization of the kinase ARAF promotes MAPK pathway activation and cell migration.
Mooz J; Oberoi-Khanuja TK; Harms GS; Wang W; Jaiswal BS; Seshagiri S; Tikkanen R; Rajalingam K
Sci Signal; 2014 Aug; 7(337):ra73. PubMed ID: 25097033
[TBL] [Abstract][Full Text] [Related]
5. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
[TBL] [Abstract][Full Text] [Related]
6. C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).
Karreth FA; DeNicola GM; Winter SP; Tuveson DA
Mol Cell; 2009 Nov; 36(3):477-86. PubMed ID: 19917255
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.
Peng SB; Henry JR; Kaufman MD; Lu WP; Smith BD; Vogeti S; Rutkoski TJ; Wise S; Chun L; Zhang Y; Van Horn RD; Yin T; Zhang X; Yadav V; Chen SH; Gong X; Ma X; Webster Y; Buchanan S; Mochalkin I; Huber L; Kays L; Donoho GP; Walgren J; McCann D; Patel P; Conti I; Plowman GD; Starling JJ; Flynn DL
Cancer Cell; 2015 Sep; 28(3):384-98. PubMed ID: 26343583
[TBL] [Abstract][Full Text] [Related]
8. Targeting the RAF-MEK-ERK pathway in cancer therapy.
Montagut C; Settleman J
Cancer Lett; 2009 Oct; 283(2):125-34. PubMed ID: 19217204
[TBL] [Abstract][Full Text] [Related]
9. High-throughput virtual screening and preclinical analysis identifies CB-1, a novel potent dual B-Raf/c-Raf inhibitor, effective against wild and mutant variants of B-Raf expression in colorectal carcinoma.
Al Shahrani M; Abohassan M; Y Alshahrani M; Hakami AR; Rajagopalan P
J Comput Aided Mol Des; 2021 Dec; 35(12):1165-1176. PubMed ID: 34727304
[TBL] [Abstract][Full Text] [Related]
10. Regulation and role of Raf-1/B-Raf heterodimerization.
Rushworth LK; Hindley AD; O'Neill E; Kolch W
Mol Cell Biol; 2006 Mar; 26(6):2262-72. PubMed ID: 16508002
[TBL] [Abstract][Full Text] [Related]
11. Discovery and optimization of a novel series of potent mutant B-Raf(V600E) selective kinase inhibitors.
Vasbinder MM; Aquila B; Augustin M; Chen H; Cheung T; Cook D; Drew L; Fauber BP; Glossop S; Grondine M; Hennessy E; Johannes J; Lee S; Lyne P; Mörtl M; Omer C; Palakurthi S; Pontz T; Read J; Sha L; Shen M; Steinbacher S; Wang H; Wu A; Ye M
J Med Chem; 2013 Mar; 56(5):1996-2015. PubMed ID: 23398453
[TBL] [Abstract][Full Text] [Related]
12. Raf: a strategic target for therapeutic development against cancer.
Beeram M; Patnaik A; Rowinsky EK
J Clin Oncol; 2005 Sep; 23(27):6771-90. PubMed ID: 16170185
[TBL] [Abstract][Full Text] [Related]
13. Non-steroidal anti-inflammatory drugs suppress the ERK signaling pathway via block of Ras/c-Raf interaction and activation of MAP kinase phosphatases.
Pan MR; Chang HC; Hung WC
Cell Signal; 2008 Jun; 20(6):1134-41. PubMed ID: 18374541
[TBL] [Abstract][Full Text] [Related]
14. Functional analysis of the regulatory requirements of B-Raf and the B-Raf(V600E) oncoprotein.
Brummer T; Martin P; Herzog S; Misawa Y; Daly RJ; Reth M
Oncogene; 2006 Oct; 25(47):6262-76. PubMed ID: 16702958
[TBL] [Abstract][Full Text] [Related]
15. RAF protein-serine/threonine kinases: structure and regulation.
Roskoski R
Biochem Biophys Res Commun; 2010 Aug; 399(3):313-7. PubMed ID: 20674547
[TBL] [Abstract][Full Text] [Related]
16. Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E.
Lee MH; Lee SE; Kim DW; Ryu MJ; Kim SJ; Kim SJ; Kim YK; Park JH; Kweon GR; Kim JM; Lee JU; De Falco V; Jo YS; Shong M
J Clin Endocrinol Metab; 2011 Jan; 96(1):E19-30. PubMed ID: 20926530
[TBL] [Abstract][Full Text] [Related]
17. Different effects of point mutations within the B-Raf glycine-rich loop in colorectal tumors on mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase and nuclear factor kappaB pathway and cellular transformation.
Ikenoue T; Hikiba Y; Kanai F; Aragaki J; Tanaka Y; Imamura J; Imamura T; Ohta M; Ijichi H; Tateishi K; Kawakami T; Matsumura M; Kawabe T; Omata M
Cancer Res; 2004 May; 64(10):3428-35. PubMed ID: 15150094
[TBL] [Abstract][Full Text] [Related]
18. An enzyme-linked immunosorbent assay for the Raf/MEK1/MAPK signaling cascade.
Mallon R; Feldberg LR; Kim SC; Collins K; Wojciechowicz D; Hollander I; Kovacs ED; Kohler C
Anal Biochem; 2001 Jul; 294(1):48-54. PubMed ID: 11412005
[TBL] [Abstract][Full Text] [Related]
19. Protein kinase C alpha trigger Ras and Raf-independent MEK/ERK activation for TPA-induced growth inhibition of human hepatoma cell HepG2.
Wen-Sheng W
Cancer Lett; 2006 Jul; 239(1):27-35. PubMed ID: 16169661
[TBL] [Abstract][Full Text] [Related]
20. Electrostatic mechanism of V600E mutation-induced B-Raf constitutive activation in colorectal cancer: molecular implications for the selectivity difference between type-I and type-II inhibitors.
Liu T; Wang Z; Guo P; Ding N
Eur Biophys J; 2019 Jan; 48(1):73-82. PubMed ID: 30218115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
